Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation

Movement Disorders

Volumn 23, Issue 6, 2008, Pages 904-907

  Forni, Gian Luca ^a   Balocco, Manuela ^a   Cremonesi, Laura ^b   Abbruzzese, Giovanni ^c   Parodi, Roberto Carlo ^d   Marchese, Roberta ^c  

^a GALLIERA HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Deferiprone; Iron chelation; NBIA

Indexed keywords

BOTULINUM TOXIN A; DEFERIPRONE; HYDROXYPYRIDONE DEFERIPRONE; QUETIAPINE; UNCLASSIFIED DRUG; IRON; IRON CHELATING AGENT;

ADRENAL CORTEX ATROPHY; ADULT; ARTICLE; BLEPHAROSPASM; CASE REPORT; CHELATION THERAPY; CHOREIC DYSKINESIA; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GAIT DISORDER; HUMAN; IRON CHELATION; IRON OVERLOAD; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE; AGED; BRAIN; METABOLISM; NERVE DEGENERATION; PATHOLOGY; TREATMENT OUTCOME;

AGED, 80 AND OVER; BRAIN; DYSKINESIAS; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; NERVE DEGENERATION; TREATMENT OUTCOME;

EID: 52449091285     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22002     Document Type: Article

References (12)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.
2. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol 2006;13:142-148.
3. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33-40.
4. Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol 2004;17:437-442.
5. Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006;27: 1230-1233.
6. Waldmeier PC, Buchle AM, Steulet AF. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol 1993;45:2417-2424.
7. Fredenburg AM, Sethi RK, Allen DD, Yokel RA. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 1996;108:191-199.
8. Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC. Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem Pharmacol 1999;57:1305-1310.
9. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 2004; 17:433-445.
10. Cohen AR. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program 2006;42-47.
11. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007; 110:401-408.
12. Delatycki MB, Camakaris J, Brooks H, et al. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neurol 1999;45:673-675.